New England Journal of Medicine· 2013Q1

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh, Sarbjit S. Saini et al.

1,080citations
Q1SCImago
2013year

Short summary

Omalizumab, an anti-IgE antibody, significantly reduced itch severity in patients with chronic idiopathic urticaria who did not respond to standard antihistamine doses.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Rheumatology

RheumatologyMedicine